Table 2. Clinical performance characteristics of serum 25-hydroxyvitamin D in patients with hematuria for diagnosis, staging, grading of bladder cancer and prognosis of non-muscle invasive bladder cancer.
| Test | AUC | Cut off | 95% CI | Sensitivity | Specificity | PPV | NPV | Accuracy | P value |
|---|---|---|---|---|---|---|---|---|---|
| ng/mL | |||||||||
| Bladder cancer versus control (bladder cancer-free) group | |||||||||
| 25-OHD | 0.991 | 24.17 | 98–100 | 0.99 | 0.81 | 0.93 | 0.96 | 0.93 | <0.001 |
| Non-muscle invasive bladder cancer versus Muscle invasive bladder cancer | |||||||||
| 25-OHD | 0.919 | 13.45 | 86–98 | 0.95 | 0.75 | 0.54 | 0.98 | 0.58 | < 0.001 |
| High grade versus low grade non-muscle invasive bladder cancer | |||||||||
| 25-OHD | 0.816 | 17.85 | 70–93 | 0.77 | 0.81 | 0.89 | 0.63 | 0.78 | < 0.001 |
| Recurrent versus non recurrent occurrence during short-term follow up non-muscle invasive bladder cancer | |||||||||
| 25-OHD | 0.487 | 15.3 | 32–66 | 0.81 | 0.83 | 0.62 | 0.93 | 0.83 | 0.917 |
AUC: area under the curve, CI: confidence interval, PPV: positive predictive value, NPV: negative predictive value.